Jonathan J Keats

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma
    Jonathan J Keats
    Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Canada
    Leuk Lymphoma 47:2289-300. 2006
  2. pmc Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
    Jonathan J Keats
    Department of Oncology, University of Alberta and Cross Cancer Institute, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada
    Blood 105:4060-9. 2005
  3. ncbi SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs
    Brian J Taylor
    Department of Oncology, Cross Cancer Institute, and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    J Immunother 28:564-75. 2005
  4. ncbi Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity
    Christopher A Maxwell
    Department of Oncology, University of Alberta and Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2
    Cancer Res 65:850-60. 2005
  5. ncbi The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma
    Robert P Evans
    Department of Oncology, University of Alberta Cross Cancer Institute, Edmonton, AB, Canada
    Br J Haematol 140:295-302. 2008
  6. ncbi In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
    Jonathan J Keats
    Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Canada
    Blood 101:1520-9. 2003
  7. ncbi RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma
    Christopher A Maxwell
    Department of Medical Oncology, Cross Cancer Institute, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada
    Blood 104:1151-8. 2004
  8. doi Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo
    Rodger E Tiedemann
    Division of Hematology and Oncology, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ 85259, USA
    Blood 113:4027-37. 2009
  9. ncbi Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice
    Linda M Pilarski
    Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada
    Exp Hematol 30:221-8. 2002
  10. pmc Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Cancer Cell 12:131-44. 2007

Detail Information

Publications10

  1. ncbi Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma
    Jonathan J Keats
    Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Canada
    Leuk Lymphoma 47:2289-300. 2006
    ..Unfortunately, despite the known association with outcome, an understanding of the mechanism(s) whereby the translocation contributes to developing and maintaining this aggressive form of myeloma remains elusive...
  2. pmc Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
    Jonathan J Keats
    Department of Oncology, University of Alberta and Cross Cancer Institute, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada
    Blood 105:4060-9. 2005
    ..In contrast, RE-IIBP is universally dysregulated and also potentially functional in all t(4;14)POS patients irrespective of fibroblast growth factor receptor 3 (FGFR3) expression or breakpoint type...
  3. ncbi SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs
    Brian J Taylor
    Department of Oncology, Cross Cancer Institute, and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    J Immunother 28:564-75. 2005
    ..These results demonstrate that SSX is a frequently expressed CTA in MM and highlight its potential as an MM vaccine candidate...
  4. ncbi Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity
    Christopher A Maxwell
    Department of Oncology, University of Alberta and Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2
    Cancer Res 65:850-60. 2005
    ..We postulate that augmentation of RHAMM expression within human cancers, including myeloma, can directly affect centrosomal structure and spindle integrity and potentially modulate apoptotic and cell cycle progression pathways...
  5. ncbi The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma
    Robert P Evans
    Department of Oncology, University of Alberta Cross Cancer Institute, Edmonton, AB, Canada
    Br J Haematol 140:295-302. 2008
    ..AZD1152 shows promise in these preclinical studies as a novel treatment for MM...
  6. ncbi In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
    Jonathan J Keats
    Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Canada
    Blood 101:1520-9. 2003
    ..003). The presence of t(4;14) is also predictive of poor response to first-line chemotherapy (P =.05). These results indicate a significant clinical impact of the t(4;14) translocation in MM that is independent of FGFR3 expression...
  7. ncbi RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma
    Christopher A Maxwell
    Department of Medical Oncology, Cross Cancer Institute, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada
    Blood 104:1151-8. 2004
    ..The RHAMM-exon4/RHAMMFL ratio in diagnostic bone marrow samples (n=101, Alberta) is an independent prognostic factor. Thus, expression and splicing of RHAMM are important molecular determinants of disease severity in MM...
  8. doi Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo
    Rodger E Tiedemann
    Division of Hematology and Oncology, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ 85259, USA
    Blood 113:4027-37. 2009
    ....
  9. ncbi Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice
    Linda M Pilarski
    Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada
    Exp Hematol 30:221-8. 2002
    ....
  10. pmc Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Cancer Cell 12:131-44. 2007
    ..These results highlight the critical importance of the NF-kappaB pathway in the pathogenesis of multiple myeloma...